NewAmsterdam Pharma Company's total assets for Q1 2025 were $818.41M, a decrease of -5.34% from the previous quarter. NAMS total liabilities were $41.05M for the fiscal quarter, a -61.68% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.